A Phase II Study of the PARP Inhibitor, INIPARIB (BSI-201), in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis.

Trial Profile

A Phase II Study of the PARP Inhibitor, INIPARIB (BSI-201), in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Dec 2014

At a glance

  • Drugs Iniparib (Primary) ; Irinotecan
  • Indications Brain metastases; Breast cancer
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 21 Oct 2014 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 16 Sep 2013 Planned End Date changed from 1 Jan 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.
    • 04 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top